Study: Tamoxifen cuts breast cancer return risk long-term

02/20/2007 | BBC

An international study concludes the hormone drug tamoxifen continues to reduce a woman's risk of breast cancer recurrence for several years after she stops taking the drug. The course of taking tamoxifen to block the effect of the estrogen hormone normally is five years, but the study said the risk reduction lasted at least as long as eight years.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL